Venom-Derived Peptides That Block KV1.3 Channels: New Approaches to Autoimmune Disease
Venom peptides targeting the KV1.3 potassium channel — critical for T cell activation in autoimmune diseases — represent a growing class of selective immunosuppressants with potential advantages over current drugs.
Quick Facts
What This Study Found
KV1.3 ion channel inhibitors derived from venom peptides selectively suppress effector memory T cells involved in autoimmune diseases, with multiple medicinal chemistry approaches being pursued to optimize them as therapeutics.
Key Numbers
ShK-186 (dalatazide) in clinical trials; targets KV1.3 selectively; derived from sea anemone ShK toxin; applications in MS, T1D, psoriasis, RA, cancer
How They Did This
Narrative review of KV1.3 biology, venom-derived peptide inhibitors, and medicinal chemistry strategies for drug optimization.
Why This Research Matters
Current immunosuppressants have broad side effects. KV1.3-selective peptides could suppress autoimmune T cells specifically without the wide immunosuppression of current drugs like cyclosporine or methotrexate.
The Bigger Picture
KV1.3 blocking peptides represent a shift from broad immunosuppression to targeted immune modulation. As the most advanced venom-derived ion channel therapeutics, they could transform autoimmune disease treatment if selectivity and delivery challenges are solved.
What This Study Doesn't Tell Us
Review of mostly preclinical data. No KV1.3 peptide drugs have completed clinical trials for autoimmune diseases. Selectivity between KV1.3 and related channels remains challenging. Peptide delivery and half-life are practical hurdles.
Questions This Raises
- ?Which KV1.3 peptide inhibitor is closest to clinical trials for autoimmune disease?
- ?Can KV1.3 blockers be made orally bioavailable?
- ?Would KV1.3 inhibition be safer than current immunosuppressants for long-term autoimmune therapy?
Trust & Context
- Key Stat:
- Selective immunosuppression KV1.3-targeting venom peptides suppress only the specific T cells driving autoimmune disease, potentially avoiding the broad immune suppression of current drugs
- Evidence Grade:
- Not applicable (narrative review). Based on preclinical pharmacology and medicinal chemistry data.
- Study Age:
- Published 2021. KV1.3 channel targeting for autoimmune disease continues in preclinical and early clinical development.
- Original Title:
- Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.
- Published In:
- Medicinal research reviews, 41(4), 2423-2473 (2021)
- Authors:
- Gubič, Špela, Hendrickx, Louise A, Toplak, Žan, Sterle, Maša, Peigneur, Steve, Tomašič, Tihomir, Pardo, Luis A, Tytgat, Jan, Zega, Anamarija, Mašič, Lucija P
- Database ID:
- RPEP-05423
Evidence Hierarchy
Frequently Asked Questions
What is KV1.3 and why target it?
KV1.3 is a potassium channel on T cells that is essential for their activation. In autoimmune diseases, overactive T cells attack the body's own tissues. Blocking KV1.3 selectively shuts down these disease-causing T cells without broadly suppressing the entire immune system.
Are there any KV1.3 drugs available?
Not yet as approved drugs. Several venom-derived KV1.3 peptide inhibitors are in preclinical development, with medicinal chemistry approaches being used to improve their drug-like properties. They could eventually provide more targeted autoimmune treatments.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05423APA
Gubič, Špela; Hendrickx, Louise A; Toplak, Žan; Sterle, Maša; Peigneur, Steve; Tomašič, Tihomir; Pardo, Luis A; Tytgat, Jan; Zega, Anamarija; Mašič, Lucija P. (2021). Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.. Medicinal research reviews, 41(4), 2423-2473. https://doi.org/10.1002/med.21800
MLA
Gubič, Špela, et al. "Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.." Medicinal research reviews, 2021. https://doi.org/10.1002/med.21800
RethinkPeptides
RethinkPeptides Research Database. "Discovery of KV 1.3 ion channel inhibitors: Medicinal chemis..." RPEP-05423. Retrieved from https://rethinkpeptides.com/research/gubic-2021-discovery-of-kv-13
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.